Publikationen (2014-2009)
-
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4 mediated microenvironmental interactions (PIM1).
Decker S, Finter J, Forde A, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray NS, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu C, Eibel H, Veelken H, Dierks C.
Mol Cancer Ther. 2014 Mar 21.
-
Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk.
Bach MP, Hug E, Werner M, Holch J, Sprissler C, Pechloff K, Zirlik K, Zeiser R, Dierks C, Ruland J, Jumaa H.
J Immunol. 2014 Feb 1;192(3):1024-33. doi: 10.4049/jimmunol.1300420.
-
DOCKing innate to adaptive signaling for persistent antibody production.
Werner, M., and Jumaa, H. (2012)
Nat Immunol 13, 525-526
-
Self-recognition and clonal selection: Autoreactivity drives the generation of B cells.
Herzog, S., and Jumaa, H. (2012)
Curr Opin Immunol 24, 166-72
-
FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination.
Alkhatib, A., Werner, M., Hug, E., Herzog, S., Eschbach, C., Faraidun, F., Köhler, F. and Jumaa H. (2012)
J Exp Med 209, 395-406
-
Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL
Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A, Herchenbach D, Jumaa H, Warmuth M, Veelken H, Dierks C (2012)
Blood. 2012 Jan 26;119(4):997-1007
-
BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition.
Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S., Klemm, L., Kweon, S., Nahar, R., Braig, M., Park, E., Kim, Y., Hofmann, W-K., Herzog, S., Jumaa, H., Koeffler, H.P., J Yu, J.J., Heisterkamp, N., Graeber, T.G., Wu, H., Ye, B.H., Melnick, A., and Müschen, M. (2011)
Nature 473: 384-388
-
N-linked glycosylation selectively regulates autonomous pre-BCR function.
Übelhart, R., Bach, M.P., Eschbach, C., Wossning, T., Reth, M., and Jumaa, H. (2010)
Nat Immunol 11, 759-65
-
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner, M., Baer, C., Prinz, G., Dierks, C., Burger, M., Zenz, T., Stilgenbauer, S., Jumaa, H., Veelken, H. and Zirlik, K. (2010)
Blood 115, 4497-4506
-
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.
Klemm, L., Duy, C., Iacobucci, I., Kuchen, S., von Levetzow, G., Feldhahn, N., Henke, N., Li, Z., Hoffmann, T.K., Kim, Y.M., Hofmann, W.K., Jumaa, H., Groffen, J., Heisterkamp, N., Martinelli, G., Lieber, M.R., Casellas, R. and Müschen, M. (2009)
Cancer Cell 16, 232-245
-
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.
Trageser, D., Iacobucci, I., Nahar, R., Duy, C., von Levetzow, G., Klemm, L., Park, E., Schuh, W., Gruber, T., Herzog, S., Kim, Y.M., Hofmann, W.K., Li, A., Storlazzi, C.T., Jäck, H.M., Groffen, J., Martinelli, G., Heisterkamp, N., Jumaa, H. and Müschen, M. (2009)
J Exp Med. 206, 1739-1753
-
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner, M., Fuchs, S., Prinz, G., Pfeifer, D., Bartholomé, K., Burger, M., Chevalier, N., Vallat, L., Timmer, J., Gribben, J.G., Jumaa, H., Veelken, H., Dierks, C. and Zirlik, K. (2009)
Cancer Res. 69, 5424-532
